Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CAF09b
- Development stage
- Unknown
- Lead developer
- Statens Serum Institut
- Modality
- Liposomes → Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intramuscular, Intranasal, Intraperitoneal
01
Overview
CAF09b is a **cationic liposomal vaccine adjuvant** developed by Statens Serum Institut. It comprises dimethyldioctadecylammonium bromide, monomycoloyl glycerol, and polyinosinic:polycytidylic acid. The formulation is designed to enhance antigen-specific cellular immunity, particularly cytotoxic CD8-positive T-cell responses, through innate immune activation and liposomal antigen delivery. CAF09b has been evaluated as an adjuvant in personalized neoantigen cancer vaccines, a Bcl-xL peptide vaccine for prostate cancer, and the CTH522 vaccine for trachoma and chlamydial infection. Croda holds an exclusive license to manufacture and commercialize the CAF adjuvant portfolio, including CAF09b. ([vac.niaid.nih.gov](https://vac.niaid.nih.gov/view?id=76))
- Other names
- CAF 09bCAF09bCAF-09bCAF®09bcationic adjuvant formulation 09b
02
Targets
TLR3 (Toll-like receptor 3)CLEC4E (Macrophage-inducible C-type lectin receptor)
Beyond the preview
Go deeper on CAF09b.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CAF09b.